Clinical Read2026-06-30
WTX-330 (IL-2 INDUKINE™)
Werewolf TherapeuticsHOWL
- Indication
- Solid tumor/s, Cancer, Non-Hodgkin lymphoma
- Stage
- Phase 1/2
- Event
- Phase 1/2 Data readout
- Details
WTX-330x2102 study. 03/07/24- Progressing study. 6/25/24- Reported initial safety & efficacy data. 11/4/25- Ph1 portion completed. Clinical update & dev. plans in Q4 2025. 12/18/25:- Part A Phase 1b/2 data showed tolerability and activity; next Part A update expected H1 2026. 03/27/26:- PR No update. 05/07/26:- PR No update.
Financial Snapshot
Market Cap
$18.6M
Price
$0.37